CVS Health Corporation (CVS)
CVS Health Corporation (CVS) is a healthcare company (healthcare plans) based in the United States. The share price is $86.71, down 2.12% on the day, which values the company at $110.94B. Price as of 17 Nov 2026, 17:23 UTC, from Yahoo Finance.
Key facts
- Share price
- $86.71−2.12% today
- Market value
- $110.94B
- P/E ratio
- 10.1×last 12 months
- Forward P/E
- 10.0×
- Dividend yield
- 3.00%
- Funk Score
- 47/100
- Against its own history
- Below its usual priceusual price $113.53
- 200-week average
- $72.8519% above
Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.
CVS Health Corporation in more detail
CVS trades at 10.1× its last twelve months' earnings, 10.0× next year's expected earnings, 0.3× sales. Measured against its own history, the price is 24% below what its usual multiples would imply ($113.53) — below its usual price. It sits 19% above its 200-week average of $72.85.
Over the last five fiscal years CVS Health Corporation has compounded revenue 8.4% a year, earnings per share -23.9% a year, free cash flow -10.3% a year. Its Funk Score is 47 out of 100 (financial strength 2.6, profitability 3.2, growth 3.9, value 9.2, each out of 10).
In its favour: Five straight years of revenue growth. Worth checking: Gross margin is shrinking.
22 of the superinvestors tracked here hold CVS, including Larry Robbins (10.0% of the portfolio), Prem Watsa (8.8% of the portfolio), Christopher Davis (4.4% of the portfolio).
Superinvestors holding CVS
22 of the investors tracked here report a position in their latest 13F filing.
- Larry Robbins Glenview Capital Management9.97% of portfolio · $499.1M · trimmed · Q2 2026
- Prem Watsa Fairfax Financial8.78% of portfolio · $232.4M · Q3 2026
- Christopher Davis Davis Advisors4.40% of portfolio · $1B · added · Q3 2026
- Samantha McLemore Patient Capital Management2.79% of portfolio · $83.1M · trimmed · Q3 2026
- Richard Pzena Pzena Investment Management2.59% of portfolio · $882.3M · trimmed · Q3 2026
- Dodge & Cox team Dodge & Cox2.12% of portfolio · $3.9B · trimmed · Q3 2026
- Andreas Halvorsen Viking Global Investors1.08% of portfolio · $379M · new · Q2 2026
- Charles Brandes (founder) Brandes Investment Partners0.85% of portfolio · $124.3M · trimmed · Q3 2026
- Mark Boyar Boyar Asset Management0.85% of portfolio · $1.4M · trimmed · Q3 2026
- John Rogers Ariel Investments0.74% of portfolio · $70.7M · added · Q3 2026
- Brandon Haley Holocene Advisors0.71% of portfolio · $310.5M · trimmed · Q2 2026
- Josef Lakonishok LSV Asset Management0.71% of portfolio · $381.8M · trimmed · Q3 2026
- Rajiv Jain GQG Partners0.45% of portfolio · $241.2M · trimmed · Q3 2026
- Jim Simons (1938–2024) Renaissance Technologies0.32% of portfolio · $233.4M · added · Q3 2026
- Steve Cohen Point72 Asset Management0.31% of portfolio · $202.9M · new · Q2 2026
- Ken Griffin Citadel Advisors0.29% of portfolio · $497.9M · trimmed · Q2 2026
- Ray Dalio (founder) Bridgewater Associates0.19% of portfolio · $45.6M · trimmed · Q2 2026
- Paul Tudor Jones Tudor Investment Corp0.16% of portfolio · $38.3M · trimmed · Q2 2026
- Israel Englander Millennium Management0.15% of portfolio · $224M · added · Q2 2026
- Primecap team Primecap Management0.13% of portfolio · $204M · trimmed · Q3 2026
- Jeremy Grantham (co-founder) GMO (Grantham, Mayo, Van Otterloo)0.10% of portfolio · $46.8M · added · Q3 2026
- Bill Nygren Harris Associates (Oakmark)0.05% of portfolio · $34.7M · trimmed · Q2 2026
Health Care companies of similar size
- Intuitive SurgicalISRG
- Vertex PharmaceuticalsVRTX
- MedtronicMDT
- Bristol-Myers SquibbBMY
- StrykerSYK
- McKessonMCK
- SanofiSNY
- ModernaMRNA
- HCA HealthcareHCA
- GSKGSK
- Regeneron PharmaceuticalsREGN
- Elevance HealthELV
Side by side:CVS vs MRNA (CVS Health Corporation vs Moderna)CVS vs HCA (CVS Health Corporation vs HCA Healthcare)CVS vs GSK (CVS Health Corporation vs GSK)CVS vs SNY (CVS Health Corporation vs Sanofi)CVS vs MCK (CVS Health Corporation vs McKesson)
All health care companies by market valueLargest companies in the United StatesAll stocks A–Z
CVS Health Corporation (CVS): questions and answers
What is CVS's P/E ratio?
CVS Health Corporation trades at 10.1× its last twelve months' earnings and 10.0× next year's expected earnings. At its fiscal year-ends over the past 18 years the P/E ranged from 11.3× to 57.1×, with a median of 15.9×.
What is CVS's PEG ratio?
CVS Health Corporation's PEG ratio is 0.22 — its P/E divided by its expected earnings growth. Around 1 is the classic sign of a price that matches the growth; well above it means the growth is being paid for in advance.
What is CVS Health Corporation's market cap?
CVS Health Corporation is valued at $110.94B at a share price of $86.71.
Is CVS overvalued or undervalued?
Against its own history, CVS is below its usual price: the price is 24% below the $113.53 implied by the median multiples it has traded at (price / earnings, price / sales, price / book, price / free cash flow). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.
Is CVS above its 200-week moving average?
Yes. CVS is 19.0% above its 200-week average of $72.85. Long-term investors watch that line because strong companies rarely trade below it for long.
How fast is CVS Health Corporation growing?
Over the last five fiscal years CVS Health Corporation's revenue grew 8.4% a year and its earnings per share -23.9% a year; over ten years revenue grew 10.1% a year.
Learn to read these numbers
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- Free cash flow and FCF yield explained
Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.
Cite this page
Funkfolio, “CVS Health Corporation (CVS) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/CVS
Underlying data: Yahoo Finance; company filings with the SEC.